 Two major investment banks cut their target prices for GSK PLC LSE:GSK, NYSE:GSK as analysts drilled down into the potential fallout from the Zantac litigation and saw the potential for total liabilities for the companies involved of over US50bn. Morgan Stanley NYSE:MS cut its price target to 1,550p from 1,860p, while Deutsche Bank cut to 1,500p from 1,750p.0 Even though the first of the legal cases against companies that sold the heartburn drug was dropped last month, Deutsche analyst Emmanuel Papadakis said a detailed review of the Zantac litigation led the bank to believe GSK and Sanofi are likely to lose the scientific argument and consequently are likely to incur liabilities. 